Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antiviralsResearch article Published on 2022-05-012022-10-05 Journal: Arab Journal of Gastroenterology [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] addition Antiviral approved clearance Combination COVID-19 COVID-19 infection Cox regression drug Efficacy and safety evaluated Factor Follow-up group highest Infection interval Mild moderate Mortality multicenter negative RT-PCR nitazoxanide Open-label Patient patients with COVID-19 polymerase chain primary endpoint Randomized Randomized controlled trial Result RT-PCR Safe SARS-CoV-2 SCT Serious Adverse Event significantly higher Sofosbuvir/ledipasvir standard care tested therapy three groups Treatment treatment for COVID-19 treatments for COVID-19 viral clearance viral clearance rate was done were recorded [DOI] 10.1016/j.ajg.2022.04.005 [Article Type] Research article
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trialControlled Trial Published on 2022-03-012023-07-01 Journal: Journal of Medicine and Life [Category] SARS, [키워드] effective curing SARS-COV-2 infection Sofosbuvir/ledipasvir [DOI] 10.25122/jml-2021-0175 PMC 바로가기 [Article Type] Controlled Trial
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literatureCase Report Published on 2017-03-012023-06-02 Journal: BMC Infectious Diseases [Category] B형 간염, [키워드] acute hepatitis DAA HBV reactivation HIV Sofosbuvir/ledipasvir [DOI] 10.1186/s12879-017-2287-y PMC 바로가기 [Article Type] Case Report